This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Novartis Weighs Sale or Spinoff of Generic Drug Unit Sandoz
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Novartis Weighs Sale or Spinoff of Generic Drug Unit Sandoz
Business

Novartis Weighs Sale or Spinoff of Generic Drug Unit Sandoz

Editorial Board Published October 26, 2021
Share
Novartis Weighs Sale or Spinoff of Generic Drug Unit Sandoz
SHARE

Novartis AG NVS -1.84% said it is considering the sale or spinoff of its generic drugs business Sandoz, a move that would focus the once-sprawling healthcare conglomerate solely on innovative prescription drugs.

Sandoz, like many generic drugmakers, has struggled with falling prices in the U.S. in recent years. Generic drugs are lower-cost versions of prescription medicines whose patents have expired. While their prices are usually far below those of the branded drugs that they imitate, increased competition has driven those prices even lower in recent years.

In response to greater competition, Novartis has pivoted Sandoz toward higher-value generics, such as biosimilars, which are near-replicas of biologic drugs made using living cells. Sandoz has also become an autonomous unit within Novartis, to give it more flexibility. But the unit, which accounts for around a fifth of total sales for Novartis, has still proven a drag on the company’s growth. In the third quarter, Sandoz sales fell 2% at constant currencies to $2.4 billion despite volumes increasing. Sandoz’s U.S. sales dropped 20%.

Novartis shares were up 0.9% in early trading.

Chief Executive Vas Narasimhan said Tuesday it was the right moment to review Sandoz’s strategic fit within Novartis. The company said it had launched a strategic review of Sandoz that would consider all options, from retaining the business to separating it. Dr. Narasimhan said he expects to complete the review by the end of next year.

Wimal Kapadia, analyst at Bernstein, said in a note that while Sandoz was a reliable cash-generator for Novartis, the unit would be more profitable, and probably generate higher returns on capital, if it were to be sold or spun out into a stand-alone business.

A separation of Sandoz would be the final step toward Novartis focusing solely on innovative drugs. Over the last decade, it has shed units that sold animal medicines, vaccines, drugstore staples, contact lenses and tools for eye surgery.

Since taking the helm in early 2018, Dr. Narasimhan has doubled down on innovative medicines and cutting-edge technologies such as gene therapies and radiopharmaceuticals, drugs that carry radioactive particles to tumors for close-range radiotherapy. He also placed a big bet on cholesterol-lowering drug inclisiran, which Novartis acquired around two years ago through a $9.7 billion deal for The Medicines Company. Inclisiran is currently under review with the Food and Drug Administration with a decision expected early next year.

The announcement of the Sandoz review came as Novartis reported that third-quarter sales increased 5% at constant currencies to $13.03 billion, driven by strong sales of some of its prescription drugs. Operating income rose 32% to $3.23 billion.

Novartis also boosted its long-term sales expectations for its two top-selling drugs, Entresto for heart failure and Cosentyx for various immunological conditions. It now expects Cosentyx to generate revenue of at least $7 billion a year at its peak, up from earlier guidance of $5 billion. It expects Entresto to make at least $5 billion a year at its peak, up from $4 billion previously.

Write to Denise Roland at [email protected]

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article UBS Earnings Driven Higher by Fees From Wealthy Clients UBS Earnings Driven Higher by Fees From Wealthy Clients
Next Article ‘Bad Bets,’ Episode 3 ‘Bad Bets,’ Episode 3

Editor's Pick

Nicki Minaj Calls Cardi B’s Daughter ‘Ugly’; Cardi Shoots Again That Nicki’s Son Is Nonverbal Because of Drug Use Throughout Being pregnant

Nicki Minaj Calls Cardi B’s Daughter ‘Ugly’; Cardi Shoots Again That Nicki’s Son Is Nonverbal Because of Drug Use Throughout Being pregnant

Studying Time: 3 minutes The Nicki Minaj vs. Cardi B beef has been occurring for years. Like, mainly for so…

By Editorial Board 4 Min Read
Maggie Baugh: Every part We Know About Keith City’s Rumored New Girlfriend
Maggie Baugh: Every part We Know About Keith City’s Rumored New Girlfriend

Studying Time: 3 minutes Is Keith City hooking up together with his…

4 Min Read
Map: See the place California FAIR Plan seeks house insurance coverage fee hikes
Map: See the place California FAIR Plan seeks house insurance coverage fee hikes

The FAIR Plan, California’s last-resort insurance coverage program for owners needing fireplace…

5 Min Read

Oponion

6 Baccarat Rouge 540 Alternate options In 2025 | Fashion

6 Baccarat Rouge 540 Alternate options In 2025 | Fashion

We independently consider all beneficial services and products. Any services…

May 3, 2025

Sure, voter fraud occurs—however it’s uncommon and safeguards exist to catch it

The nation’s multilayered election processes present…

October 13, 2024

Bitnomial sues SEC over XRP futures, challenges company’s continued declare that XRP is a safety

SEC Commissioner Mark Uyeda discusses the…

October 11, 2024

What to know earlier than Cal kicks off vs. Duke at Memorial Stadium

DUKE AT CAL Information: Cal 4-1 total,…

October 4, 2025

Jane Goodall Explanation for Demise: Legendary Conservationist Was 91

Studying Time: 3 minutes Dr. Jane…

October 1, 2025

You Might Also Like

Russia for Business: Experts Who Help Drive Decisions
BusinessTrending

Russia for Business: Experts Who Help Drive Decisions

Amid sanctions and the restructuring of global supply chains, understanding the logic behind Russia’s actions has become a practical necessity…

4 Min Read
The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40
BusinessTrending

The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40

Across the nation, a quiet but powerful workforce shift is underway. Increasingly, women over 40 are seeking side hustles to…

4 Min Read
Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution
Business

Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution

At a time when billions of linked objects are reshaping industries, Thales has achieved a vital safety certification for its…

4 Min Read
Soracom IoT Platform Achieves SOC 2 Kind 2 Compliance for Safety, Availability, and Confidentiality
Business

Soracom IoT Platform Achieves SOC 2 Kind 2 Compliance for Safety, Availability, and Confidentiality

Soracom, Inc., right now introduced that it has efficiently achieved System and Group Controls (SOC) 2 Kind 2 compliance, reinforcing…

2 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?